---
schema_version: "secwatch.filing_event.v1"
accession: "0001827635-26-000016"
form_type: "8-K"
ticker: "MANE"
cik: "0001827635"
company_name: "Veradermics, Inc"
filed_at: "2026-05-12T12:32:47+00:00"
generated_at: "2026-05-12T12:35:16.807021+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Veradermics Q1 net loss $27.2M, positive Phase 2/3 results for VDPHL01 hair loss drug

## Summary
- Net loss $27.2M for Q1 2026 vs $12.4M Q1 2025; R&D $20.9M, G&A $8.9M.
- Positive Phase 2/3 topline results for VDPHL01 in male pattern hair loss; 12-month data H2 2026.
- Enrollment completed in Study '304' (Phase 3, male PHL); topline data H2 2026. Study '306' (female PHL) enrolling.
- Raised ~$766.8M gross from IPO and follow-on; cash $390.8M at Mar 31, 2026, expected to fund into 2030.

## SEC filing metadata
- accession: 0001827635-26-000016
- form_type: 8-K
- ticker: MANE
- cik: 0001827635
- company_name: Veradermics, Inc
- filed_at: 2026-05-12T12:32:47+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000016/0001827635-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000016/mane-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001827635-26-000016
- JSON: https://secwatch.observer/filing/0001827635-26-000016.json
- Plain text: https://secwatch.observer/filing/0001827635-26-000016.txt

## Key facts
- Earnings Releases
  Veradermics, Inc reported the first quarter ended March 31, 2026 results: net income Net loss was $27.2 million, for the first quarter of 2026, as compared to a net loss of $12.4 million for the first quar.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss was $27.2 million, for the first quarter of 2026, as compared to a net loss of $12.4 million for the first quar
  - Result: reported results
  source text: Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate and clinical progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000016/0001827635-26-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.